Awakening of Dormant Breast Cancer Cells in the Bone Marrow DOI Open Access
Robert Wieder

Cancers, Journal Year: 2023, Volume and Issue: 15(11), P. 3021 - 3021

Published: June 1, 2023

Up to 40% of patients with breast cancer (BC) have metastatic cells in the bone marrow (BM) at initial diagnosis localized disease. Despite definitive systemic adjuvant therapy, these survive BM microenvironment, enter a dormant state and recur stochastically for more than 20 years. Once they begin proliferate, recurrent macrometastases are not curable, generally succumb their Many potential mechanisms initiating recurrence been proposed, but no predictive data generated. This manuscript reviews proposed that maintain BC cell dormancy microenvironment discusses supporting specific recurrence. It addresses well-described secretory senescence, inflammation, aging, adipogenic conversion, autophagy, effects trauma surgery, sympathetic signaling, transient angiogenic bursts, hypercoagulable states, osteoclast activation, epigenetic modifications cells. review approaches either eliminating micrometastases or maintaining state.

Language: Английский

Regulation of metastatic organotropism DOI
Karen J. Dunbar, Gizem Efe, Katherine Cunningham

et al.

Trends in cancer, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

Citations

4

Unveiling the role of cellular dormancy in cancer progression and recurrence DOI Creative Commons
Évelyne Collignon

Current Opinion in Oncology, Journal Year: 2024, Volume and Issue: 36(2), P. 74 - 81

Published: Jan. 2, 2024

Purpose of review Cellular dormancy is a major contributor to cancer progression and recurrence. This explores recent findings on the molecular mechanisms implicated in investigates potential strategies improve therapeutic interventions. Recent Research reveals complex multifaceted phenomenon. Providing latent reservoir tumor cells with reduced proliferation enhanced drug-tolerance, dormant emerge from clonally diverse population after therapy or at metastatic sites. These exhibit distinct transcriptional epigenetic profiles, involving downregulation Myc mechanistic target rapamycin (mTOR) pathways, induction autophagy. Senescence traits, under control factors such as p53, also contribute significantly. The microenvironment can either promote prevent establishment, notably through involvement T NK within niche. Strategies combat dormancy-related relapse include direct elimination cells, sustaining prolong survival, awakening re-sensitize them antiproliferative drugs. Summary Improving our understanding primary secondary sites provides valuable insights into patient care prevention.

Language: Английский

Citations

3

Awakening of Dormant Breast Cancer Cells in the Bone Marrow DOI Open Access
Robert Wieder

Cancers, Journal Year: 2023, Volume and Issue: 15(11), P. 3021 - 3021

Published: June 1, 2023

Up to 40% of patients with breast cancer (BC) have metastatic cells in the bone marrow (BM) at initial diagnosis localized disease. Despite definitive systemic adjuvant therapy, these survive BM microenvironment, enter a dormant state and recur stochastically for more than 20 years. Once they begin proliferate, recurrent macrometastases are not curable, generally succumb their Many potential mechanisms initiating recurrence been proposed, but no predictive data generated. This manuscript reviews proposed that maintain BC cell dormancy microenvironment discusses supporting specific recurrence. It addresses well-described secretory senescence, inflammation, aging, adipogenic conversion, autophagy, effects trauma surgery, sympathetic signaling, transient angiogenic bursts, hypercoagulable states, osteoclast activation, epigenetic modifications cells. review approaches either eliminating micrometastases or maintaining state.

Language: Английский

Citations

6